Position in AZN
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$730,793,186
New position
Shares Held
3,705,472
first reported quarter
Ownership
0.239%
of shares outstanding
% of Portfolio
0.56%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 99.99689648174376.ToString("F0")%
Shared 0.0031035182562437393.ToString("F0")%
None 0.ToString("F0")%
Derivatives in AZN
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$39,444,000
PutShares
200,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026CITIGROUP INC holds $4,719,307,282 across 18 Drug Manufacturers - General names. AZN ranks #2 (15.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
1,091,983 | $1,004,373,202 | |
| 2 | AZN |
Astrazeneca PLC
This page
|
3,705,472 | $730,793,186 | |
| 3 | JNJ |
Johnson & Johnson
|
2,832,497 | $692,375,564 | |
| 4 | ABBV |
AbbVie Inc.
|
2,089,885 | $454,529,087 | |
| 5 | PFE |
Pfizer Inc
|
15,493,259 | $435,050,711 | |
| 6 | MRK |
Merck & Co., Inc.
|
2,779,106 | $334,298,659 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
2,300,271 | $320,588,766 | |
| 8 | AMGN |
Amgen Inc
|
828,097 | $291,365,928 |
All Filings in AZN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $730,793,186 | 3,705,472 | Shares | Defined | 2026-05-11 | |
| 2026-03-31 | $39,444,000 | 200,000 | Put | Defined | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||